Literature DB >> 1493081

Co-regulation of phenytoin and tolbutamide metabolism in humans.

W Tassaneeyakul1, M E Veronese, D J Birkett, C J Doecke, M E McManus, L N Sansom, J O Miners.   

Abstract

1. The disposition of phenytoin and tolbutamide was compared in eighteen healthy young adults separately administered single therapeutic doses (sodium phenytoin 300 mg, tolbutamide 500 mg) of the two drugs. 2. Within the group, ratios of ranges of total and unbound areas under the plasma concentration-time curves were similar for both drugs. 3. There were significant (P < 0.001) correlations between total (r = 0.88) and unbound (r = 0.86) areas under the plasma phenytoin and tolbutamide concentration-time curves. 4. The results are consistent with the involvement of the same cytochrome P-450 isoenzyme(s) in the metabolism of tolbutamide and phenytoin.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1493081      PMCID: PMC1381450     

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  31 in total

1.  Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance.

Authors:  W Zilly; D D Breimer; E Richter
Journal:  Eur J Clin Pharmacol       Date:  1975-12-19       Impact factor: 2.953

2.  Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers.

Authors:  M E Veronese; J O Miners; D Randles; D Gregov; D J Birkett
Journal:  Clin Pharmacol Ther       Date:  1990-03       Impact factor: 6.875

Review 3.  Genetic factors influencing the metabolism of tolbutamide.

Authors:  D J Back; M L Orme
Journal:  Pharmacol Ther       Date:  1989       Impact factor: 12.310

4.  Relationship between the metabolism of antipyrine, hexobarbitone and theophylline in man as assessed by a 'cocktail' approach.

Authors:  J H Schellens; J H van der Wart; M Danhof; E A van der Velde; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1988-10       Impact factor: 4.335

5.  The effect of sulphinpyrazone on oxidative drug metabolism in man: inhibition of tolbutamide elimination.

Authors:  J O Miners; T Foenander; S Wanwimolruk; A S Gallus; D J Birkett
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

Review 6.  Phenytoin: pharmacogenetic polymorphism of 4'-hydroxylation.

Authors:  T Inaba
Journal:  Pharmacol Ther       Date:  1990       Impact factor: 12.310

7.  Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9.

Authors:  M E Veronese; P I Mackenzie; C J Doecke; M E McManus; J O Miners; D J Birkett
Journal:  Biochem Biophys Res Commun       Date:  1991-03-29       Impact factor: 3.575

8.  The effect of different oral anticoagulants on diphenylhydantoin (DPH) and tolbutamide metabolism.

Authors:  L Skovsted; M Kristensen; M Hansen; K Siersbaek-Nielsen
Journal:  Acta Med Scand       Date:  1976

9.  Hepatic metabolism of tolbutamide: characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition.

Authors:  R G Knodell; S D Hall; G R Wilkinson; F P Guengerich
Journal:  J Pharmacol Exp Ther       Date:  1987-06       Impact factor: 4.030

10.  Normal metabolism of debrisoquine and theophylline in a slow tolbutamide metaboliser.

Authors:  J O Miners; L M Wing; D J Birkett
Journal:  Aust N Z J Med       Date:  1985-06
View more
  15 in total

1.  Pharmacokinetics of tolbutamide in ethnic Chinese.

Authors:  A S Gross; S Bridge; G M Shenfield
Journal:  Br J Clin Pharmacol       Date:  1999-02       Impact factor: 4.335

2.  Absence of an inhibitory effect of omeprazole and nizatidine on phenytoin disposition, a marker of CYP2C activity.

Authors:  K A Bachmann; T J Sullivan; L Jauregui; J H Reese; K Miller; L Levine
Journal:  Br J Clin Pharmacol       Date:  1993-10       Impact factor: 4.335

Review 3.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

Review 4.  Differential kinetics of phenytoin in elderly patients.

Authors:  K A Bachmann; R J Belloto
Journal:  Drugs Aging       Date:  1999-09       Impact factor: 3.923

5.  Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans.

Authors:  D J Carlile; N Hakooz; M K Bayliss; J B Houston
Journal:  Br J Clin Pharmacol       Date:  1999-06       Impact factor: 4.335

Review 6.  Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.

Authors:  S H Preskorn
Journal:  Clin Pharmacokinet       Date:  1997       Impact factor: 6.447

Review 7.  Drug interactions with proton pump inhibitors.

Authors:  P Unge; T Andersson
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

Review 8.  Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.

Authors:  T Andersson
Journal:  Clin Pharmacokinet       Date:  1996-07       Impact factor: 6.447

9.  Assessment of inter-individual variability in predicted phenytoin clearance.

Authors:  Thomas M Polasek; Sebastian Polak; Matthew P Doogue; Amin Rostami-Hodjegan; John O Miners
Journal:  Eur J Clin Pharmacol       Date:  2009-12       Impact factor: 2.953

10.  Novel in vitro dynamic metabolic system for predicting the human pharmacokinetics of tolbutamide.

Authors:  Cai-Fu Xue; Zhe Zhang; Yan Jin; Bin Zhu; Jun-Fen Xing; Guo Ma; Xiao-Qiang Xiang; Wei-Min Cai
Journal:  Acta Pharmacol Sin       Date:  2018-04-12       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.